Shanghai Yizhong Pharmaceutical Co Ltd Total Assets
Shanghai Yizhong Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) holds total assets worth CN¥1.54 Billion CNY (≈ $225.89 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shanghai Yizhong Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
Total assets of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Shanghai Yizhong Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Shanghai Yizhong Pharmaceutical Co Ltd - Asset Composition Analysis
Shanghai Yizhong Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Shanghai Yizhong Pharmaceutical Co Ltd total assets breakdown as of December 2024. Shanghai Yizhong Pharmaceutical Co Ltd's total assets of CN¥1.54 Billion consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.5% |
| Accounts Receivable | CN¥54.45 Million | 3.8% |
| Inventory | CN¥45.17 Million | 3.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥8.36 Million | 0.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Shanghai Yizhong Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Yizhong Pharmaceutical Co Ltd's current assets represent 53.6% of total assets in 2024, an increase from 48.3% in 2017.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2024, up from 1.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shanghai Yizhong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Shanghai Yizhong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.67 | 18.01 | 24.15 |
| Quick Ratio | 7.84 | 17.37 | 23.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥610.92 Million | CN¥798.86 Million | CN¥125.34 Million |
Shanghai Yizhong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Yizhong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.43 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | -8.0% |
| Total Assets | CN¥1.45 Billion |
| Market Capitalization | $1.11 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Yizhong Pharmaceutical Co Ltd's assets below their book value (0.76x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Yizhong Pharmaceutical Co Ltd's assets decreased by 8.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total assets of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.45 Billion ≈ $211.89 Million |
-7.97% |
| 2023-12-31 | CN¥1.57 Billion ≈ $230.23 Million |
+16.15% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.22 Million |
+12.83% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.68 Million |
+363.88% |
| 2020-12-31 | CN¥258.81 Million ≈ $37.87 Million |
-6.77% |
| 2019-12-31 | CN¥277.62 Million ≈ $40.62 Million |
+21.06% |
| 2018-12-31 | CN¥229.33 Million ≈ $33.56 Million |
+7.29% |
| 2017-12-31 | CN¥213.74 Million ≈ $31.28 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more